CAS 28860-95-9
:Carbidopa
Description :
Carbidopa est un composé pharmaceutique principalement utilisé dans le traitement de la maladie de Parkinson et de ses symptômes. Il agit comme un inhibiteur de la dopa décarboxylase, ce qui empêche la conversion de la lévodopa en dopamine dans les tissus périphériques, augmentant ainsi la disponibilité de la lévodopa pour le cerveau, où elle peut être convertie en dopamine. Ce mécanisme améliore les effets thérapeutiques de la lévodopa tout en minimisant les effets secondaires tels que les nausées et les vomissements. Carbidopa est souvent administré en combinaison avec la lévodopa pour améliorer l'efficacité du traitement. Le composé est caractérisé par sa formule moléculaire, qui comprend des atomes de carbone, d'hydrogène, d'azote et d'oxygène. Il est généralement administré par voie orale et est bien absorbé dans le tractus gastro-intestinal. Carbidopa a un profil de toxicité relativement faible, mais peut provoquer des effets secondaires tels que des vertiges, une bouche sèche ou une dyskinésie chez certains patients. Sa pharmacocinétique implique une absorption rapide et une demi-vie relativement courte, nécessitant plusieurs doses tout au long de la journée pour un effet thérapeutique optimal.
Formule :C10H14N2O4
InChI :InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
Code InChI :InChIKey=TZFNLOMSOLWIDK-JTQLQIEISA-N
SMILES :[C@@](CC1=CC(O)=C(O)C=C1)(C(O)=O)(NN)C
Synonymes :- (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
- (-)-<span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
- (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid
- (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate
- (2S)-2-(Aminoazaniumyl)-3-(3,4-dihydroxyphenyl)-2-methylpropanoate
- (2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
- (S)-Carbidopa
- (αS)-α-Hydrazinyl-3,4-dihydroxy-α-methylbenzenepropanoic acid
- 1-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
- <span class="text-smallcaps">L</span>-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
- <span class="text-smallcaps">L</span>-Carbidopa
- <span class="text-smallcaps">L</span>-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
- <span class="text-smallcaps">L</span>-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
- <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
- <span class="text-smallcaps">L</span>-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
- <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
- <span class="text-smallcaps">L</span>-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
- <span class="text-smallcaps">L</span>-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
- <span class="text-smallcaps">L</span>-α-Methyldopahydrazine
- Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-
- Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-
- Cabidopa
- Carbidopa
- HMD
- Hydrazino-α-methyldopa
- Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, <span class="text-smallcaps">L</span>-
- Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, L-
- L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
- L-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid
- L-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
- L-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid
- L-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
- L-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid
- L-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid
- L-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid
- L-α-Methyldopahydrazine
- Lodosin
- Lodosyn
- Mk 486
- N-Aminomethyldopa
- α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid
- α-Methyldopahydrazine
- Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-
- L-alpha-Methyldopahydrazine
- 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
- Tocris-0455
- 1-(Mesithylene-2-sulfonyl)-3-nitro-1,2,4-triazole
- L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
- Carbidopum [INN-Latin]
- alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
- CCRIS 5093
- 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
- (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)
- (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid
- SMR000058235
- NCGC00024596-01
- (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
- alpha-hydrazino-3,4-dihydroxy-alpha-methyl-(S )-
- Carbidopa anhydrous
- Benzenepropanoic acid
- alpha-Methyldopahydrazine
- L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic aci d
- alpha-HYDRAZINO-3,4-DIHYDROXY-alpha-METHYL-L-KINSON
- Hadrazino-alpha-methyldopa
- MLS000069628
- Voir plus de synonymes
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
7 produits concernés.
Carbidopa Monohydrate
CAS :Formule :C10H14N2O4·H2ODegré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Light yellow powder to crystalineMasse moléculaire :244.253,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic acid
CAS :Formule :C10H14N2O4Degré de pureté :99%Couleur et forme :SolidMasse moléculaire :226.2292(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic Acid
CAS :(S)-3-(3,4-Dihydroxyphenyl)-2-Hydrazinyl-2-Methylpropanoic AcidDegré de pureté :97%Masse moléculaire :226.23g/molCarbidopa
CAS :Formule :C10H14N2O4Couleur et forme :White To Off-White SolidMasse moléculaire :226.23Carbidopa
CAS :<p>Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM).</p>Formule :C10H14N2O4Degré de pureté :98.01% - ≥98%Couleur et forme :SolidMasse moléculaire :226.23(S)-(-)-Carbidopa
CAS :Produit contrôlé<p>Stability Unstable in Solution<br>Applications (S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.<br>References Henry, G.M. et al.: Psychosom. Med., 38, 95 (1976); Leguire, L.E. et al.: Invest. Ophthalmol. Vis. Sci. 34, 3090 (1993); Deleu, D. et al.: Naun. Schmied. Arch. Pharmacol. 348: 576 (1993);<br></p>Formule :C10H14N2O4Couleur et forme :NeatMasse moléculaire :226.23





